# CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes Patients With Stage 4 CKM Syndrome

Study · id `cardio:ct-nct07351643` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07351643](<https://clinicaltrials.gov/study/NCT07351643>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT07351643

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 110 participants.

## Technical summary

Registry record NCT07351643. Randomized; no masking; primary purpose treatment. Start 2026-06-25 (actual); primary completion 2027-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 110 participants (planned count; ClinicalTrials.gov record NCT07351643, source copy `cardio:ctgov-nct07351643-2026-10-30`, retrieved 2026-10-31)
- Started: 2026-06-25 (actual) (ClinicalTrials.gov record NCT07351643, source copy `cardio:ctgov-nct07351643-2026-10-30`, retrieved 2026-10-31)
- Primary completion: 2027-06-30 (anticipated) (ClinicalTrials.gov record NCT07351643, source copy `cardio:ctgov-nct07351643-2026-10-30`, retrieved 2026-10-31)
- Completion: 2027-06-30 (anticipated) (ClinicalTrials.gov record NCT07351643, source copy `cardio:ctgov-nct07351643-2026-10-30`, retrieved 2026-10-31)
- Countries: China (ClinicalTrials.gov record NCT07351643, source copy `cardio:ctgov-nct07351643-2026-10-30`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07351643-2026-10-30`, retrieved 2026-10-31)

## The registry's words

- Brief title: CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes Patients With Stage 4 CKM Syndrome
- Acronym: DAPA-PCAT
- Condition: ACS (Acute Coronary Syndrome)
- Condition: SGLT2 Inhibitors
- Intervention (Drug): Dapagliflozin
- Lead sponsor: Shenyang Northern Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Shenyang Northern Hospital (`cardio:org-shenyang-northern-hospital`)

## Provenance

Content hash: 35c00fd60f4bc49ef7cea5a3dd901aa3bf7bafd466c8dc997f936ae6bfdf8747
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
